Impact of viral load kinetics and recurrent cytomegalovirus infection in kidney transplantation

BackgroundWe have shown that viral load kinetics during the first cytomegalovirus (CMV) viremic episode are important predictors of kidney transplant failure. This article evaluates the incremental hazard of recurrent CMV viremia and of viral load kinetics on graft and patient survival.MethodsThis r...

Full description

Saved in:
Bibliographic Details
Main Authors: Sabina Dobrer, Karen R. Sherwood, Kimberly Davis, James H. Lan, John Gill, Nancy Matic, Paul A. Keown
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-08-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1600289/full
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850043706354171904
author Sabina Dobrer
Karen R. Sherwood
Kimberly Davis
James H. Lan
James H. Lan
John Gill
Nancy Matic
Paul A. Keown
Paul A. Keown
author_facet Sabina Dobrer
Karen R. Sherwood
Kimberly Davis
James H. Lan
James H. Lan
John Gill
Nancy Matic
Paul A. Keown
Paul A. Keown
author_sort Sabina Dobrer
collection DOAJ
description BackgroundWe have shown that viral load kinetics during the first cytomegalovirus (CMV) viremic episode are important predictors of kidney transplant failure. This article evaluates the incremental hazard of recurrent CMV viremia and of viral load kinetics on graft and patient survival.MethodsThis retrospective cohort study included 2,464 sequential kidney transplants performed between 2008 and 2018. Care was delivered according to a uniform provincial protocol, and patients were followed for up to 13 years with standardized therapy and continuous monitoring of clinical course, CMV infection, viral load kinetics, and graft and patient outcomes.Results434/2,464 (17.6%) patients (age range: 2–80 years) developed CMV infection, of whom 67/434 (15.4%) had 150 episodes of recurrent infection. Mean cumulative CMV frequency reached an asymptote of 21% at 500 days, with the highest rate (43%) in D+/R-, and lowest (1%) in D-/R- risk groups. Multinomial adjusted regression described a composite risk phenotype that included increased age, non-Caucasian race, diabetes, D+/R- status, and delayed graft function (p<0.005). Median cumulative viral load kinetic values rose progressively with the number of viremic episodes, maximum viral load rising from 3.8–5.1 log10 IU/mL, mean duration of viremia from 15–116 days, and viral AUC from 56.1–492.9 log10 IU/mL*days in patients with multiple episodes of CMV viremia. Predicted probability of graft failure and death were closely related to the cumulative duration of viremia and total viral load, with respective survival values declining to 30% and 7% in patients with elevated viremic indices and defined composite risk phenotype.ConclusionsPatients with a recurrent CMV viremia post-transplant are at exceptionally high risk of transplant failure as measured by graft loss or death, which is determined by both composite risk phenotype and CMV viral load kinetics. Conventional prophylaxis appears to be inadequate to protect these patients from recurrent infection and its serious consequences, and alternative treatment strategies, with continuous long-term monitoring and rapid, effective therapy, are vital to maximize transplant success.
format Article
id doaj-art-9811ba97ad364a7e9d8bb97d52a216e2
institution DOAJ
issn 1664-3224
language English
publishDate 2025-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj-art-9811ba97ad364a7e9d8bb97d52a216e22025-08-20T02:55:09ZengFrontiers Media S.A.Frontiers in Immunology1664-32242025-08-011610.3389/fimmu.2025.16002891600289Impact of viral load kinetics and recurrent cytomegalovirus infection in kidney transplantationSabina Dobrer0Karen R. Sherwood1Kimberly Davis2James H. Lan3James H. Lan4John Gill5Nancy Matic6Paul A. Keown7Paul A. Keown8Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, CanadaDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, CanadaGlobal Evidence & Outcomes Within R&D, Takeda Development Center Americas, Inc., Lexington, MA, United StatesDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, CanadaDepartment of Medicine, University of British Columbia, Vancouver, BC, CanadaDepartment of Medicine, University of British Columbia, Vancouver, BC, CanadaDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, CanadaDepartment of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, CanadaDepartment of Medicine, University of British Columbia, Vancouver, BC, CanadaBackgroundWe have shown that viral load kinetics during the first cytomegalovirus (CMV) viremic episode are important predictors of kidney transplant failure. This article evaluates the incremental hazard of recurrent CMV viremia and of viral load kinetics on graft and patient survival.MethodsThis retrospective cohort study included 2,464 sequential kidney transplants performed between 2008 and 2018. Care was delivered according to a uniform provincial protocol, and patients were followed for up to 13 years with standardized therapy and continuous monitoring of clinical course, CMV infection, viral load kinetics, and graft and patient outcomes.Results434/2,464 (17.6%) patients (age range: 2–80 years) developed CMV infection, of whom 67/434 (15.4%) had 150 episodes of recurrent infection. Mean cumulative CMV frequency reached an asymptote of 21% at 500 days, with the highest rate (43%) in D+/R-, and lowest (1%) in D-/R- risk groups. Multinomial adjusted regression described a composite risk phenotype that included increased age, non-Caucasian race, diabetes, D+/R- status, and delayed graft function (p<0.005). Median cumulative viral load kinetic values rose progressively with the number of viremic episodes, maximum viral load rising from 3.8–5.1 log10 IU/mL, mean duration of viremia from 15–116 days, and viral AUC from 56.1–492.9 log10 IU/mL*days in patients with multiple episodes of CMV viremia. Predicted probability of graft failure and death were closely related to the cumulative duration of viremia and total viral load, with respective survival values declining to 30% and 7% in patients with elevated viremic indices and defined composite risk phenotype.ConclusionsPatients with a recurrent CMV viremia post-transplant are at exceptionally high risk of transplant failure as measured by graft loss or death, which is determined by both composite risk phenotype and CMV viral load kinetics. Conventional prophylaxis appears to be inadequate to protect these patients from recurrent infection and its serious consequences, and alternative treatment strategies, with continuous long-term monitoring and rapid, effective therapy, are vital to maximize transplant success.https://www.frontiersin.org/articles/10.3389/fimmu.2025.1600289/fullkidney transplantcytomegalovirusCMVrecurrent infectionviral load kineticsclinical outcomes
spellingShingle Sabina Dobrer
Karen R. Sherwood
Kimberly Davis
James H. Lan
James H. Lan
John Gill
Nancy Matic
Paul A. Keown
Paul A. Keown
Impact of viral load kinetics and recurrent cytomegalovirus infection in kidney transplantation
Frontiers in Immunology
kidney transplant
cytomegalovirus
CMV
recurrent infection
viral load kinetics
clinical outcomes
title Impact of viral load kinetics and recurrent cytomegalovirus infection in kidney transplantation
title_full Impact of viral load kinetics and recurrent cytomegalovirus infection in kidney transplantation
title_fullStr Impact of viral load kinetics and recurrent cytomegalovirus infection in kidney transplantation
title_full_unstemmed Impact of viral load kinetics and recurrent cytomegalovirus infection in kidney transplantation
title_short Impact of viral load kinetics and recurrent cytomegalovirus infection in kidney transplantation
title_sort impact of viral load kinetics and recurrent cytomegalovirus infection in kidney transplantation
topic kidney transplant
cytomegalovirus
CMV
recurrent infection
viral load kinetics
clinical outcomes
url https://www.frontiersin.org/articles/10.3389/fimmu.2025.1600289/full
work_keys_str_mv AT sabinadobrer impactofviralloadkineticsandrecurrentcytomegalovirusinfectioninkidneytransplantation
AT karenrsherwood impactofviralloadkineticsandrecurrentcytomegalovirusinfectioninkidneytransplantation
AT kimberlydavis impactofviralloadkineticsandrecurrentcytomegalovirusinfectioninkidneytransplantation
AT jameshlan impactofviralloadkineticsandrecurrentcytomegalovirusinfectioninkidneytransplantation
AT jameshlan impactofviralloadkineticsandrecurrentcytomegalovirusinfectioninkidneytransplantation
AT johngill impactofviralloadkineticsandrecurrentcytomegalovirusinfectioninkidneytransplantation
AT nancymatic impactofviralloadkineticsandrecurrentcytomegalovirusinfectioninkidneytransplantation
AT paulakeown impactofviralloadkineticsandrecurrentcytomegalovirusinfectioninkidneytransplantation
AT paulakeown impactofviralloadkineticsandrecurrentcytomegalovirusinfectioninkidneytransplantation